All News
Filter News
Found 185 articles
-
Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021
1/21/2021
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in the Regeneron Science Talent Search 2021, the nation's oldest and most prestigious science and math competition for high school seniors.
-
BioSpace takes a look at some of the announcements that occurred Monday and will continue to update throughout the week.
-
Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
1/12/2021
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of the casirivimab and imdevimab antibody cocktail for use in non-hospitalized COVID-19 patients to meet the federal government's Operation Warp Speed goals
-
Late Friday, the FDA gave the green light to Regeneron's REGN-COV2, a combination of casirivimab and imdevimab.
-
Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
11/22/2020
Initial doses of REGEN-COV2 will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S. government allocation program
-
Regeneron Included on Dow Jones Sustainability World Index for Second Consecutive Year
11/16/2020
Regeneron Pharmaceuticals, Inc. announced that it has been included on the highly selective Dow Jones Sustainability World Index for the second consecutive year.
-
Regeneron Reports Third Quarter 2020 Financial and Operating Results
11/5/2020
Regeneron Pharmaceuticals, Inc. announced financial results for the third quarter of 2020 and provided a business update.
-
Regeneron Once Again Earns #1 Ranking in Science Magazine's Top Biopharma Companies to Work For
10/29/2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company was once again ranked as the top company to work for by Science magazine in its annual Top Employers Survey of the global biotech and pharmaceutical industry.
-
Biopharma Industry Donates More Money to Democrats, Reversing Trend of Higher Republican Support
10/9/2020
Since 1990, drug companies’ political committees have largely donated to Republican presidential campaigns. But that trend has noticeably reversed come the 2020 election cycle, according to a new report from the Center for Responsive Politics which shows that approximately 51% of total contributi... -
Regeneron stated that under its agreement with the U.S. government for initial doses of the cocktail, if an EUA is granted the government “has committed to making these doses available to the American people at no cost and would be responsible for their distribution.”
-
Regeneron and Roche Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Cocktail for COVID-19
8/19/2020
REGN-COV2 is Regeneron's two-antibody 'cocktail' currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection
-
Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19
8/19/2020
REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection.
-
Regeneron Reports Second Quarter 2020 Financial and Operating Results
8/5/2020
Regeneron Pharmaceuticals, Inc. announced financial results for the second quarter of 2020 and provided a business update.
-
Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2020 for Exemplary Research on Predicting Crop Yield, Machine Learning Algorithms and Reducing Emissions in Industrial Gas Burners
7/30/2020
$250,000 top award goes to Lillian Petersen of New Mexico in nation's oldest and most prestigious STEM competition for high school seniors
-
BARDA Procures Regeneron's REGN-EB3 Investigational Ebola Treatment for National Preparedness
7/29/2020
REGN-EB3 is a novel anti-viral antibody cocktail developed using the same rapid response technologies as REGN-COV2, Regeneron's investigational COVID-19 antibody cocktail
-
This deal with BARDA and the DoD supports continuing the manufacturing in order for it to be immediately available in the U.S. if the clinical trials are successful.
-
Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail
7/7/2020
Regeneron Pharmaceuticals, Inc. announced that, as part of Operation Warp Speed, the BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense have awarded Regeneron a $450 million contract to manufacture and supply REGN-COV2.
-
Regeneron Recognized as Healthcare Sector Leader on "The Civic 50" List of the Most Community-Minded Companies in the United States
6/10/2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it has been named to The Civic 50 for the fourth consecutive year and honored for the first time as the sector leader for healthcare. The Civic 50 is an initiative of Points of Light, the world's largest organization dedicated to volunteer service, and recognizes t
-
MJH Life Sciences™ Hosts Pharma CEO Roundtable on Market Impact of COVID-19
6/4/2020
Hosted by its popular industry brand, Pharmaceutical Executive®, MJH Life Sciences™ organized a closed virtual roundtable, “Pharmaceutical CEO Leadership During the Pandemic.”
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 13, 2020.